Orilanolimab

• CAT Number: I041552
• CAS Number: 2066544-85-0
• Purity: ≥95%

Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity[1][2].
Orilanolimab (10 nM, 50 nM, and 100 nM; 48 h) inhibits interferon IFN-γ production in CD11c+ Ag-presenting cells (APCs) from B2MTG/TGFCGRTTG/TGFcgrt-/- mice[1].
Orilanolimab (20 mg/kg; i.v.) significantly reduces the plasma concentration of HuLys11 in mouse model[1].
Orilanolimab (10-100 mg/kg; i.v.; once per 5 weeks) causes dose-dependent and specific reduction of total circulating levels of IgG cynomolgus monkeys[1].

Reference

[1]. Blumberg LJ, et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv. 2019 Dec 18;5(12):eaax9586.
 [Content Brief]

[2]. Blumberg L, et al. SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases[J]. Blood, 2017, 130: 3483.